Intercept Announces FDA Acceptance of sNDA for Ocaliva
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first...
Intercept Announces Findings from Long-term Extension of Landmark POISE Trial
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (œAlfasigma) and Intercept Pharmaceuticals, Inc. (œIntercept) announced today the completion of the...
Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period
Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences
It’s been an uphill battle for Intercept Pharmaceuticals in the three years since the FDA first nixed its attempt to bring Ocaliva to patients with nonalcoholic steatohepatitis (NASH)-related liver fibrosis.
MORRISTOWN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Ocaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarterCompany updates full-year 2023 Ocaliva net sales guidance to $320 million to $340...
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...